Based on treatment addressed against MM, the NR-MM were 34/122 (28%) of patients treated with anti-CD38-based immunotherapy, 12/122 (10%) of patients treated with proteasome inhibitors (PI), and 36/122 (30%) of patients treated with immunomodulatory agents. Here, CD38 is linked to Miyoshi myopathy.